Glenmark Pharma shares jump up to 4% on Phase 1 results for blood cancer drug

T cell activation, proliferation and soluble BCMA reduction were observed in most patients at effective doses, according to Glenmark.

Leave a Reply

Your email address will not be published. Required fields are marked *